Healthcare Funds Capture Massive Gains in GSK's Buyout of RAPT Therapeutics
San Francisco, Sunday, 22 March 2026.
Institutional funds secured massive profits by aggressively accumulating RAPT Therapeutics shares just months before GSK’s $2.2 billion buyout, capitalizing on a nearly 90 percent premium in early 2026.
Precision Accumulation by Smart Money
The acquisition of clinical-stage biotech firm RAPT Therapeutics (NASDAQ: RAPT) by British pharmaceutical giant GSK plc officially concluded on March 3, 2026 [1][7][8]. While some earlier market projections anticipated a second-quarter close [“Source 5 suggested a Q2 2026 close, conflicting with Source 1 which confirms the merger officially closed on March 3, 2026”], the expedited finalization locked in a $2.2 billion valuation, pricing RAPT shares at $58.00 each [1][2][5]. This figure represented a 39 percent premium over the stock’s closing price on January 16, 2026, just prior to the deal’s public announcement [1][5].
The Science Driving the Valuation
GSK’s motivation for the $2.2 billion expenditure centers almost entirely on ozureprubart, RAPT’s late-stage anti-IgE therapy designed to target food allergies [1][2][5]. The clinical candidate aims to disrupt the current treatment landscape by offering a significantly extended half-life [5]. If successful, ozureprubart could be dosed every 12 weeks, presenting a stark improvement in patient compliance compared to the current standard of care, Xolair, which requires injections every two to four weeks [1][5]. GSK’s chief scientific officer has publicly described the asset as a “potential best-in-class treatment” [1].
Executive Exits and Post-Merger Realities
While institutional investors locked in substantial profits, RAPT’s internal leadership also utilized the March 3, 2026, merger closure to cleanly liquidate their holdings [1]. CEO Brian Russell Wong and CFO Rodney KB Young both tendered their shares and cashed out equity awards at the $58.00 deal price [1]. Additionally, Director Mary Ann Gray disposed of 4,956 shares through the tender offer [1]. Market analysts suggest this comprehensive exit by insiders indicates a lack of confidence in the asset’s post-acquisition value, effectively shifting the entirety of the clinical and financial risk to GSK [1].